Search

靜脈滴入注射用血凝酶過敏一例

硫糖鋁混懸凝膠混合血凝酶與血管夾用于防治內鏡下息肉切除術后出血的隨機對照研究

目的 探討硫糖鋁混懸凝膠混合血凝酶用于防治內鏡下息肉切除術后出血的臨床效果。 方法 納入 2014 年 4 月—2015 年 3 月在消化內鏡中心行內鏡檢查發現直結腸息肉，并行內鏡下腸道息肉黏膜切除術患者 112 例，隨機分成藥物組和血管夾組，每組各 56 例，分別予以術后創面噴灑硫糖鋁混懸凝膠混合血凝酶及血管夾止血處理，觀察兩種方法操作時間、止血成功率、術后再出血的發生率及創面愈合情況。 結果 藥物組和血管夾組分別有 15 例和 13 例出現術中即時出血，兩組差異無統計學意義（P>0.05）。兩組術中觀察均成功止血，未追加其他止血方法。藥物組和血管夾組平均操作時間分別為（58±16）、（192±94） s，兩組差異有統計學意義（P<0.05）。術后觀察，藥物組無再出血，血管夾組 1 例再出血，兩組差異無統計學意義（P>0.05）。兩組患者術后 1 個月復查創面均愈合良好。 結論 硫糖鋁混懸凝膠混合血凝酶用于防治內鏡下息肉切除術后出血是一種簡單、經濟、有效的止血方法。

Investigation on the Effects of Hemocoagulase in the Treatment of Upper Gastrointestinal Hemorrhage

目的:觀察用白眉蛇毒血凝酶(邦亭)治療上消化道出血的療效。方法 上消化道出血患者90例,隨機分為治療組和對照組,所有病例均給予擴容及調整水電解質紊亂,靜滴奧美拉唑42.6mg,每日1次;靜滴卡絡磺鈉60mg,每日1次,重度貧血者予輸血。治療組再應用邦亭4 KU加生理鹽水20mL口服,每日2次,對照組用去甲腎上腺素8mg加生理鹽水90mL,每日分3次口服。結果 治療組總有效率93.75%,對照組總有效率8095%,兩組臨床療效差異有統計學意義(Plt;0.05)結論:白眉蛇毒血凝酶是一種有效的、安全的治療上消化道出血的藥物,在臨床止血治療中值得推廣應用。

Effectiveness of haemocoagulase agkistrodon versus tranexamic acid and sodium chloride in the prevention and treatment of perioperative bleeding: a real-world study

ObjectiveTo compare the effectiveness of haemocoagulase agkistrodon and tranexamic acid and sodium chloride in the prevention and treatment of perioperative bleeding in a real world setting. MethodsA research database was constructed based on the records of inpatient visits using haemocoagulase agkistrodon and tranexamic acid and sodium chloride according to the SuValue? database from January 1, 2016 to December 31, 2020. The patients were divided into two groups according to the different interventions. After matching with a 1∶1 propensity score, the effectiveness of two groups was compared. ResultsA total of 858 patients were included in each of the two groups, and there was no statistically significant difference in baseline characteristics between the two groups (P>0.05). Research results showed that patients using haemocoagulase agkistrodon had significantly reduced length of hospital stay, decrease in hematocrit, average estimated surgical bleeding, and decrease in hemoglobin (P<0.01). ConclusionHaemocoagulase agkistrodon has better effectiveness than tranexamic acid and sodium chloride for reducing perioperative blood loss based on current real world evidence.

Efficacy and Safety of Hemocoagulase on Surgical Incision: A Systematic Review

ObjectiveTo evaluate the efficacy and safety of all kinds of hemocoagulase on operative incisions. MethodsDatabases including Web of Science, MEDLINE, EMbase, EBSCO, PubMed, CNKI, WanFang Data and VIP were electronically searched to collect randomized controlled trials (RCTs) about hemocoagulase on operative incisions from the inception to June 20th, 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by RevMan 5.2 software. ResultsA total of 16 RCTs involving 1 867 patients were included. The results of meta-analysis showed that, compared with the control group, the hemostatic time (MD=-37.84, 95%CI -52.72 to -22.96, P<0.000 01), blood loss volume per unit area (MD=-0.09, 95%CI -0.10 to -0.07, P<0.000 01), PT of the first postoperative day (MD=-0.37, 95%CI -0.65 to -0.09, P=0.009) were significantly shorter in the hemocoagulase group. However, no significant differences were found in APTT, TT and FIB between two groups. ConclusionHemocoagulase can reduce hemostatic time and blood loss volume in surgical incisions. Due to the limited quantity and quality of the included studies, the above conclusion needs to be further verified by more high quality studies.